Substance use disorders are associated with significant morbidity and mortality that affects individuals and their families. Preventing the onset of an SUD in adolescence remains a critical area of clinical and public health significance.
Substance Use Disorder
Anxiety disorders occur in 18% to 28% of the US general population during any 12-month period. In anxiety disorder, there is a 33% to 45% 12-month prevalence rate for a comorbid substance use disorder (SUD).
In this article, we attempt to leverage state-of-the-art research findings to provide empirically informed perspectives and practices related to these issues.
What is your experience with patients who may decide to quit multiple substances simultaneously? Is it overambitious?
The recent death of Amy Winehouse has brought the question of why some people get addicted to alcohol and/or drugs and others don’t.
Which tool is helpful in screening for sexual addiction? Is the symptom severity in women treated for substance abuse generally equivalent to that of males? Structural abnormalities in which brain areas have been associated with substance abuse? These questions and more in this quiz.
When it comes to analgesics, many options and various factors must be weighed to make the best choice for each patient.
Advances in the fields of neuropsychological assessment and neuroimaging have enormously expanded our knowledge about the profile and severity of cognitive deficits in patients with substance use disorders.
The COMBINE study was only one trial designed by academics to maximize internal scientific validity. It excluded individuals with other significant psychiatric and medical illnesses (more often the rule than the exception in some clinical settings)—individuals deemed too severely ill or who needed hospitalization.
In this Special Report, Helen M. Pettinati, PhD, and William D. Dundon, PhD, discuss prevalence, assessment, clinical features, and treatment issues with respect to individuals with co-occurring major depression and alcohol dependence.